Ten patients previously taking pervitine (for 8.8 years on average) showed a decrease in the body mass index, 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol concentrations and an increase in bone alkaline phosphatase; the other examined parameters remained unchanged. The bone mineral density showed low and very low values in five and four patients, respectively, related to the Z-score according to NHANNES III tables in a U.S. reference study. There are several reasons, other than the pervitine intake, why the patients could have low bone mineral density and calcium-phosphorus metabolism disorders: low calcium and vitamin D intake, lack of body exercise, nicotine and alcohol abuse.

• Klíčová slova
• Pervitin,
• MeSH
• denzitometrie metody   MeSH
• kosti a kostní tkáň metabolismus   MeSH
• kostní denzita účinky léků   MeSH
• lidé MeSH
• osteoporóza chemicky indukované   krev   MeSH
• poruchy metabolismu fosforu chemicky indukované   MeSH
• poruchy metabolismu vápníku chemicky indukované   MeSH
• poruchy spojené s užíváním amfetaminu metabolismus   MeSH
• Check Tag
• lidé MeSH